Risk factor
Good trading liquidity
Profitability factor
Undervalued vs peers
About
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid...
Company Valuation
From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, undervalued on EV/EB
Target Price
The average target price of COLL is 55 and suggests 21% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell